Recruiting
Phase 1
Phase 2

A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06305767

Conditions

Bladder Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

V940

Placebo

Enfortumab Vedotin

Surgery (RC plus PLND)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information